Form 4: Pediatrix Executive Kasandra Rossi Reports Stock Transactions

Kasandra H. Rossi, EVP, CFO and Treasurer of Pediatrix Medical Group, Inc., reported transactions involving restricted stock grants and tax withholdings.

Summary

• Kasandra H. Rossi, EVP, CFO and Treasurer of Pediatrix Medical Group, Inc., filed a Form 4 detailing stock transactions.
• On June 1, 2026, 31,800 restricted shares were granted, with a reported acquisition value of $0.
• Also on June 1, 2026, 3,701 restricted shares were disposed of, valued at $21.54 per share, totaling $80,001.54, which were withheld for tax payments upon vesting.
• Following these transactions, Rossi beneficially owns 101,399 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting standard executive compensation practices rather than significant company performance indicators or strategic shifts.

Positives

• Receipt of a significant restricted stock grant (31,800 shares) as part of an annual equity award, indicating continued incentive and alignment with the company's performance.
• The grant of restricted stock suggests management confidence in the company's future prospects, as these awards are often tied to vesting schedules and performance metrics.

Negatives

• A portion of restricted shares (3,701) were withheld for tax payments, representing a cost to the executive and a reduction in the net shares received.

Risks

• The vesting schedule for the restricted shares (25% on June 1, 2027, 25% on June 1, 2028, and 50% on June 1, 2029) means that the full benefit of the award is contingent on continued employment and potentially other performance conditions.
• The value of the withheld shares ($21.54) could be lower than the market price at the time of future vesting, impacting the net gain for the executive.

Future Outlook

The vesting schedule for the restricted shares indicates a multi-year outlook for the executive's compensation tied to these awards, with full vesting occurring by June 1, 2029. The grant itself implies management's expectation of continued company value.

Industry Context

StockSavvy.ai notes that the issuance of restricted stock to key executives like CFOs is a common practice in the healthcare services industry to incentivize long-term performance and retention. Pediatrix Medical Group, Inc. (MD) operates within this framework, aligning executive compensation with shareholder value.

Stakeholder Impact

• Shareholders: The restricted stock grant aligns executive interests with long-term company performance, potentially benefiting shareholders if the company's value increases.
• Employees: The grant to a key executive may reflect overall positive performance or incentive structures within the company.
• Management: The transaction directly impacts the beneficial ownership and compensation of Kasandra H. Rossi.

Next Steps

• Vesting of restricted shares on June 1, 2027, June 1, 2028, and June 1, 2029, subject to the terms of the Plan.

Key Dates

Keywords

Form 4, SEC Filing, Pediatrix Medical Group, MD, Stock Transaction, Restricted Stock, Equity Award, Insider Trading, Beneficial Ownership, Kasandra Rossi, CFO